Life expectancy after HIV diagnosis based on national hiv surveillance data from 25 states, United States

Journal of Acquired Immune Deficiency Syndromes

Volumn 53, Issue 1, 2010, Pages 124-130

  Harrison, Kathleen McDavid ^a   Song, Ruiguang ^a   Zhang, Xinjian ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

HIV; Life expectancy; Surveillance data; United States

Indexed keywords

ADULT; AFRICAN AMERICAN; ARTICLE; EUROPEAN AMERICAN; FEMALE; HEALTH SURVEY; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; LIFE TABLE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE; SEXUAL BEHAVIOR; UNITED STATES; VIRUS TRANSMISSION; VITAL STATISTICS;

ADOLESCENT; ADULT; AFRICAN AMERICANS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HIV INFECTIONS; HUMANS; LIFE EXPECTANCY; LIFE TABLES; MALE; UNITED STATES; YOUNG ADULT;

EID: 74049164246     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181b563e7     Document Type: Article

References (43)

1. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet. 1998;352:1725-1730.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
3. Adult Prevention and Treatment of Opportunistic Infections Guidelines Working Group. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. March 24, 2009. MMWR 2009; 58 (early release) pp. 1-198. Available at: http://www.cdc.gov/mmwr/preview/ mmwrhtml/rr58e324a1.htm Accessed December 11 2008, www.cdc.gov/mmwr/preview/ mmwrhtml/rr58e324a1.htm. Accessed December 11, 2008
4. U.S. Department of Health and Human Services. Healthy People 2010. 2nd ed. With Understanding and Improving Health and Objectives for Improving Health. 2 vols. Washington, DC: U.S. Government Printing Office, November 2000. Available at http://www.healthypeople.gov/ default.htm. Accessed August 30, 2009.
5. Gardner JW, Sanborn JS. Years of potential life lost (YPLL)-what does it measure? Epidemiology. 1990;1:322-329.
6. Burnet NG, Jefferies SJ, Benson RJ, et al. Years of life lost (YLL) from cancer is an important measure of population burden-and should be considered when allocating research funds. Br J Cancer. 2005;92:241-245.
7. Jaggy C, von Overbeck J, Ledergerber B, et al; and the Swiss HIV Cohort Study. Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. Lancet. 2003;362:877-878.
8. Keiser O, Taffe P, Zwahlen M, et al; and the Swiss HIV Cohort Study. All cause mortality in the Swiss HIV cohort study from 1990 to 2001 in comparison with the Swiss population. AIDS. 2004;18:1835-1843.
9. van Sigham A, Danner S, Ghani AC, et al; on behalf of the ATHENA National Observation Cohort Study. Mortality in patients with successful initial response to highly active antiretroviral therapy isstill higher than in non-HIV-infected individuals. J Acquir Immune Defic Syndr. 2005;40:212-218.
10. Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med. 2007; 146:87-95
11. The Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372:293-299.
12. Bhaskaran K, Hamouda O, Sannes M, et al; for the CASCADE Collaboration. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA. 2008;300: 51-59.
13. Hall HI, McDavid K, Ling Q, et al. Determinants of progression to AIDS or death after HIV diagnosis, United States, 1996 to 2001. Ann Epidemiol. 2006;16:824-833.
14. McDavid Harrison K, Ling Q, Song R, et al. County-level socioeconomic status and survival after HIV diagnosis, United States. Ann Epidemiol. 2008;18:919-927.
15. Lima VD, Hogg RS, Harrigan PR, et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS. 2007;21:685-692.
16. Guidelines for defining public health research and public health non-research. Centers for Disease Control and Prevention Web site. Available at: http://www.cdc.gov/od/science/regs/hrpp/researchdefinition.htm. Revised October 4, 1999. Accessed December 7, 2008.
17. Protection of human subjects. 45 CFR Part 46. Department of Health and Human Services Web site. Available at: http://www.hhs.gov/ohrp/ documents/OHRPRegulations.pdf. Revised June 23, 2005. Accessed December 7, 2008.
18. Arias E. United States Life Tables, 2004. National Vital Statistics Reports. Vol 56. No 9. Hyattsville, MD: National Center for Health Statistics; 2007. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr56/nvsr56- 09.pdf. Accessed February 16, 2009.
19. Green TA. Using surveillance data to monitor trends in the AIDS epidemic. Stat Med. 1998;17:143-154.
20. McDavid Harrison K, Kajese T, Hall IH, et al. Risk factor redistribution of the national HIV/AIDS surveillance data: an alternative approach. Public Health Rep. 2008;123:618-627.
21. Kung HC, Hoyert DL, XU J, et al. Deaths: Final Data for 2005. National Vital Statistics Reports. Vol 56. No 10. Hyattsville, MD: National Center for Health Statistics; 2008. Available at: http://www.cdc.gov/nchs/data/ nvsr/nvsr56/nvsr56-10.pdf. Accessed January 10, 2009
22. National Center for Health Statistics. Estimates of the July 1, 2000-July 1, 2007, United States resident population from the Vintage 2007 postcensal series by year, county, age, sex, race, and Hispanic origin, prepared under a collaborative arrangement with the U.S. Census Bureau. Available at: http://www.cdc.gov/nchs/about/major/dvs/popbridge/datadoc.htm#vintage 2007. Accessed January 10, 2009
23. Centers for Disease Control and Prevention. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged, 18 months and for HIV infection and AIDS among children aged 18 months to,13 years-United States, 2008. MMWR Recomm Rep. 2008; 57(RR-10):1-12.
24. Lyles CM, Kay LS, Crepaz N, et al. Best-evidence interventions: findings from a systematic review of HIV behavioral interventions for US populations at high risk, 2000-2004. Am J Public Health. 2007;97: 133-143. (Pubitemid 46067695)
25. Chander G, Himelhoch S, Moore RD. Substance abuse and psychiatric disorders in HIV-positive patients: epidemiology and impact on antiretroviral therapy. Drugs. 2006;66:769-789.
26. Orckstroh JK, Mocroft A, Soriano V, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis. 2005;192:992-1002. (Pubitemid 41266795)
27. Palacio H, Shiboski CH, Yelin EH, et al. Access to and utilization of primary care services among HIV-infected women. J Acquir Immune Defic Syndr. 1999;21:293-300.
28. Braithwaite RS, Justice AC, Chang CH, et al. Estimating the proportion of patients infected with HIV who will die of comorbid diseases. Am J Med. 2005;118:890-898.
29. Adih WK, Selik RM. Trends in Diseases Reported on Death Certificates that mentioned HIV Infection, USA, 1996-2005. Orally presented at: the APHA Annual Meeting; San Diego, CA; October 29, 2008.
30. Losina E, Schackman B, Sadownik S, et al. Disparities in survival attributable to suboptimal HIV care in the US: influence of gender and race/ethnicity. Presented at: 14th Conference on Retroviruses and Opportunistic Infections, February 27, 2007; Los Angeles, CA.
31. Viard JP, Mocroft A, Chiesi A, et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis. 2001;183:1290-1294.
32. Hinkin CH, Hardy DJ, Mason KI, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS. 2004;18(Suppl 1):S19-S25.
33. Lai DJ, Tarwater PM, Hardy RJ. Measuring the impact of HIV/AIDS, heart disease and malignant neoplasms on life expectancy in the USA from 1987 to 2000. Public Health. 2006;120:486-492.
34. Galvan FH, Bing EG, Fleishman JA, et al. The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: results from the HIV Cost and Services Utilization Study. J Stud Alcohol. 2002;63:179-186.
35. Mamary EM, Bahrs D, Martinez S. Cigarette smoking and the desire to quit among individuals living with HIV. AIDS Patient Care STDs. 2002; 16:39-42.
36. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy: results from the DAD study. AIDS. 2003;17:1179-1193.
37. Centers for Disease Control and Prevention. HIV/AIDS and Viral Hepatitis. Available at: http://www.cdc.gov/hepatitis/Populations/hiv.htm. Accessed February 22, 2009.
38. Myers T, Allman D, Xu K, et al. The prevalence and correlates of hepatitis C virus (HCV) infection and HCV-HIV co-infection in a community sample of gay and bisexual men. Int J Infect Dis. 2009. In press.
39. Des Jarlais DC, Semaan S. HIV prevention for injecting drug users: the first 25 years and counting. Psychosom Med. 2008;70:606-611
40. Centers for Disease Control and Prevention. HIV prevalence estimates-United States 2006. MMWR Morb Mortal Wkly Rep 2008, 57, 1073-1076.
41. Phillips AN, Dunn D, Sabin C, et al. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS. 2005;19:487-494.
42. Zwahlen M, Lundgren JD. Commentary: death in the era of potent antiretroviral therapy: shifting causes, new challenges. Int J Epidemiol. 2005;34:130-131
43. Centers for Disease Control and Prevention. Advancing HIV prevention: new strategies for a changing epidemic-United States. MMWR Morb Mortal Wkly Rep. 2003;52:329-332.